Genetic risk factors for venous thrombosis.

[1]  B. Dahlbäck,et al.  Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. , 2000, Blood.

[2]  E R McCabe,et al.  Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. , 2000, American journal of human genetics.

[3]  P. Harvey,et al.  A single nucleotide polymorphism at nucleotide −1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels , 2000, British journal of haematology.

[4]  J. Corral,et al.  The TFPI 536C →T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis , 2000, Thrombosis and Haemostasis.

[5]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[6]  F. Rosendaal,et al.  High levels of coagulation factor XI as a risk factor for venous thrombosis. , 2000, The New England journal of medicine.

[7]  D. Arveiler,et al.  Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Témoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[8]  P. Grant,et al.  Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.

[9]  T. Baglin,et al.  The Factor V R2 Allele: Risk of Venous Thromboembolism, Factor V Levels and Resistance to Activated Protein C , 2000, Thrombosis and Haemostasis.

[10]  D. Lane,et al.  Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. , 2000, Blood.

[11]  M. Margaglione,et al.  Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) , 1999 .

[12]  A. Iolascon,et al.  Homozygous Prothrombin Gene Mutationand Ischemic Cerebrovascular Disease , 1999, Acta Haematologica.

[13]  F. España,et al.  Hereditary Homozygous Heparin Cofactor II Deficiency and the Risk of Developing Venous Thrombosis , 1999, Thrombosis and Haemostasis.

[14]  Takako Saito,et al.  Thrombomodulin with the Asp468Tyr mutation is expressed on the cell surface with normal cofactor activity for protein C activation , 1999, British journal of haematology.

[15]  D. Lane,et al.  Structural and Functional Implications of the Intron/Exon Organization of the Human Endothelial Cell Protein C/Activated Protein C Receptor (EPCR) Gene: Comparison With the Structure of CD1/Major Histocompatibility Complex 1 and 2 Domains , 1999, Blood.

[16]  W. Prohaska,et al.  The 536C→T Transition in the Human Tissue Factor Pathway Inhibitor (TFPI) Gene Is Statistically Associated with a Higher Risk for Venous Thrombosis , 1999, Thrombosis and Haemostasis.

[17]  J. Emmerich,et al.  No Link between the TFPI V264M Mutation and Venous Thromboembolic Disease , 1999, Thrombosis and Haemostasis.

[18]  D. Lillicrap,et al.  Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF :Ag levels : Identification of three novel single nucleotide polymorphisms in the vWF gene promoter , 1999 .

[19]  P. Reitsma,et al.  Factor XIII Val34Leu Is a Genetic Factor Involved in the Aetiology of Venous Thrombosis , 1999, Thrombosis and Haemostasis.

[20]  D. Arveiler,et al.  Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects : impact of the V264M substitution on plasma levels of TFPI. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[21]  P. Grant,et al.  Association of a Common Polymorphism in the Factor XIII Gene With Venous Thrombosis , 1999 .

[22]  V. Nicaud,et al.  The Factor V Gene A4070G Mutation and the Risk of Venous Thrombosis , 1999, Thrombosis and Haemostasis.

[23]  J. Fontcuberta,et al.  Homozygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism. , 1999, Haematologica.

[24]  W. Prohaska,et al.  A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI. , 1998, Blood.

[25]  P. Board,et al.  The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. , 1998, Blood.

[26]  Y. Kwong,et al.  Clinical significance of Arg306 mutations of factor V gene. , 1998, Blood.

[27]  P. Grant,et al.  A Common Coding Polymorphism in the FXIII A-subunit Gene (FXIIIVAL34LEU) Affects Cross-linking Activity , 1998, Thrombosis and Haemostasis.

[28]  C. Mannhalter,et al.  A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. , 1998, Blood.

[29]  P. Reitsma,et al.  Geographic Distribution of the 20210 G to A Prothrombin Variant , 1998, Thrombosis and Haemostasis.

[30]  A. Carter,et al.  Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. , 1998, Stroke.

[31]  R. Liang,et al.  A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. , 1998, Blood.

[32]  T. Baglin,et al.  Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. , 1998, Blood.

[33]  A. Carter,et al.  Association of a Common Polymorphism in the Factor XIII Gene with Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[34]  K. Maršál,et al.  Factor V Q506 Mutation (Activated Protein C Resistance) Associated with Reduced Intrapartum Blood Loss – a Possible Evolutionary Selection Mechanism , 1998, Thrombosis and Haemostasis.

[35]  T. Matsuo,et al.  [Activated protein C resistance]. , 1998, Ryoikibetsu shokogun shirizu.

[36]  Bengt Zöller,et al.  A Novel Thrombomodulin Gene Mutation in a Patient Suffering from Sagittal Sinus Thrombosis , 1997, Thrombosis and Haemostasis.

[37]  E. Sacchi,et al.  A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype , 1997 .

[38]  A. Duncan,et al.  A patient homozygous for a mutation in the prothrombin gene 3'-untranslated region associated with massive thrombosis. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[39]  J. Emmerich,et al.  Protein C and protein S deficiencies. , 1997, Seminars in hematology.

[40]  D. Lane,et al.  Thrombomodulin gene mutations associated with myocardial infarction. , 1997, Circulation.

[41]  R. Marlar,et al.  Thrombomodulin Gene Variations and Thromboembolic Disease , 1997, Thrombosis and Haemostasis.

[42]  J. Barrett,et al.  von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.

[43]  P. Reitsma,et al.  Protein S Deficiency: A Database of Mutations , 1997, Thrombosis and Haemostasis.

[44]  X. Estivill,et al.  Absence of linkage between type III protein S deficiency and the PROS1 and C4BP genes in families carrying the protein S Heerlen allele. , 1997, Blood.

[45]  Bengt Zöller,et al.  A Common Thrombomodulin Amino Acid Dimorphism Is Associated with Myocardial Infarction , 1997, Thrombosis and Haemostasis.

[46]  J. Griffin,et al.  A single genetic origin for a common Caucasian risk factor for venous thrombosis. , 1997, Blood.

[47]  D. Cooper,et al.  Antithrombin Mutation Database: 2nd (1997) Update , 1997, Thrombosis and Haemostasis.

[48]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[49]  F. Bernardi,et al.  A Heparin Cofactor II Mutation (HCII Rimini) Combined with Factor V Leiden or Type I Protein C Deficiency in Two Unrelated Thrombophilic Subjects , 1996, Thrombosis and Haemostasis.

[50]  C. Esmon,et al.  The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Pasi,et al.  Lack of Activated Protein C Resistance in Healthy Hong Kong Chinese Blood Donors - Correlation with Absence of Arg506-Gln Mutation of Factor V Gene , 1996, Thrombosis and Haemostasis.

[52]  K. Kario,et al.  Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). , 1996, Blood.

[53]  F. Locatelli,et al.  Cancer in patients on renal replacement therapy in Lombardy, Italy , 1996, The Lancet.

[54]  P. Reitsma,et al.  World distribution of factor V Leiden mutation. , 1996, Lancet.

[55]  M. Monden,et al.  Coagulation Factor V Leiden Mutation May Have a Racial Background , 1995, Thrombosis and Haemostasis.

[56]  M. Aiach,et al.  The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. , 1995, Blood.

[57]  J. Clegg,et al.  World distribution of factor V Leiden , 1995, The Lancet.

[58]  P. Reitsma,et al.  Protein C Deficiency: A Database of Mutations, 1995 Update , 1995, Thrombosis and Haemostasis.

[59]  P. Reitsma,et al.  High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) , 1995, Blood.

[60]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[61]  D. Tollefsen.  Insight into the Mechanism of Action of Heparin Cofactor II , 1995, Thrombosis and Haemostasis.

[62]  K.,et al.  Homozygous Antithrombin Deficiency: Report of Two New Cases (99 Leu to Phe) Associated with Arterial and Venous Thrombosis , 1994, Thrombosis and Haemostasis.

[63]  P. Reitsma,et al.  Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis , 1994, Thrombosis and Haemostasis.

[64]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[65]  M. Blombäck,et al.  Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. , 1994, Genomics.

[66]  T. Edgington,et al.  Structural biology of tissue factor, the initiator of thrombogenesis in vivo 1 , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  P. Fay,et al.  Regulation of blood coagulation by the protein C system , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  C. Esmon.  The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[70]  J. Sadler.  von Willebrand factor. , 1991, The Journal of biological chemistry.

[71]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. , 1991, British heart journal.

[72]  M. Scully,et al.  Late-onset homozygous protein C deficiency , 1991, The Lancet.

[73]  P. Reitsma,et al.  The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. , 1991, Blood.

[74]  B. Dahlbäck.  Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System , 1991, Thrombosis and Haemostasis.

[75]  P. Reitsma,et al.  A Frequent Thrombomodulin Amino Acid Dimorphism Is not Associated with Thrombophilia , 1991, Thrombosis and Haemostasis.

[76]  T. Meade,et al.  A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[77]  P. Reitsma,et al.  Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. , 1990, Blood.

[78]  R. Marlar,et al.  Neonatal purpura fulminans associated with homozygous protein S deficiency , 1990, The Lancet.

[79]  R. Trapp,et al.  Free protein S levels are elevated in familial C4b-binding protein deficiency. , 1990, Blood.

[80]  P. Reitsma,et al.  Two Genes Homologous with Human Protein S cDNA Are Located on Chromosome 3 , 1987, Thrombosis and Haemostasis.

[81]  S. Humphries,et al.  ROLE OF GENETIC VARIATION AT THE FIBRINOGEN LOCUS IN DETERMINATION OF PLASMA FIBRINOGEN CONCENTRATIONS , 1987, The Lancet.

[82]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[83]  S. Bajaj,et al.  Activation of human factor VII during clotting in vitro. , 1985, Blood.

[84]  C. Esmon,et al.  Familial protein S deficiency is associated with recurrent thrombosis. , 1984, The Journal of clinical investigation.

[85]  J. Katz,et al.  INHERITED PROTEIN C DEFICIENCY AND COUMARIN-RESPONSIVE CHRONIC RELAPSING PURPURA FULMINANS IN A NEWBORN INFANT , 1983, The Lancet.

[86]  S. Orkin,et al.  Molecular heterogeneity of inherited antithrombin III deficiency. , 1983, The New England journal of medicine.

[87]  J. Griffin,et al.  Deficiency of protein C in congenital thrombotic disease. , 1981, The Journal of clinical investigation.

[88]  A. Bloom.  Haemostasis and thrombosis , 1981 .

[89]  W. Kisiel.  Human Plasma Protein C: ISOLATION, CHARACTERIZATION, AND MECHANISM OF ACTIVATION BY α-THROMBIN , 1979 .

[90]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[91]  U. Abildgaard.  Binding of thrombin to antithrombin III. , 1969, Scandinavian journal of clinical and laboratory investigation.

[92]  Greiner Ac,et al.  Schizophrenia-melanosis: cause or side-effect? , 1965 .